Healthtech Solutions Inc. (HLTT) Broadens Portfolio with Acquisition of Varian Bio, Enters Precision Cancer Care Market

• Healthtech Solutions is acquiring Varian Biopharmaceuticals, developer of atypical protein kinase C iota inhibitors within thriving precision oncology market
• Varian Bio is developing two pre-clinical experimental drugs, VAR-101 for basal cell carcinoma and VAR-102 for a variety of solid tumors, including pancreatic, colorectal and NSCLC.
• Varian Bio will join MediScan, RevHeart in Healthtech’s portfolio of innovative healthcare technology companies

For more than three decades, scientists searched to find the connection between human cancers and the protein kinase C group with little success. Things changed around 2006 with the discovery of atypical protein kinase C iota (aPKC iota, or aPKCi), an oncogene believed to be instrumental in regulating tumors in several types of cancer. Research is ongoing today by companies like Varian Biopharmaceuticals to advance innovative aPKC iota inhibitors in the field of precision oncology. Varian Bio is now joining the family of companies at Healthtech Solutions (OTC: HLTT), a New York-based company focused on acquiring and investing in strategic cutting-edge healthcare technological opportunities. Varian Bio is coming under the Healthtech Solutions’ umbrella via the parent company acquiring a wholly-owned subsidiary, Healthtech Oncology Inc., which will own a 100% interest in Varian Bio. Varian Bio will join MediScan Inc., a developer of technology that converts 2D images from… Read More>> NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.